RxDoctor Payments Data

Jose Cura, MD

Internal Medicine · Tampa, FLNPI 1629059167

Payments from drug & device makers

$2,792in general payments, 2019–2025

Across 150 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$392
  • Pfizer$285
  • AstraZeneca$260
  • E.r. Squibb & Sons, L.L.C.$224
  • Boehringer Ingelheim$209
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$197
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,792100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,792 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$152,540
Medicare patients
644
Services billed
1,792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban547$483,908
EntrestoSacubitril/Valsartan105$121,212
XareltoRivaroxaban89$101,107
Repatha SureclickEvolocumab74$81,982
FarxigaDapagliflozin Propanediol82$74,268
JardianceEmpagliflozin52$45,573
Repatha SyringeEvolocumab25$26,840
VascepaIcosapent Ethyl46$18,178
BrilintaTicagrelor11$10,032
Dofetilide22$7,829
Labetalol Hcl320$6,958
Bisoprolol Fumarate288$6,608
Torsemide406$6,064
Diltiazem 12hr ErDiltiazem Hcl45$5,355
Metoprolol Succinate478$5,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$285$483,908547 claims
NovartisEntresto$392$121,212105 claims
Johnson & JohnsonXarelto$52$101,10789 claims
AstraZenecaFarxiga, Brilinta$260$84,30093 claims
Boehringer IngelheimJardiance, Pradaxa$209$49,72865 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →